Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Jul;80(10):1648–1651. doi: 10.1038/sj.bjc.6690576

Significance of serum-soluble CD95 (Fas/APO-1) on prognosis in renal cell cancer patients

M Kimura 1, Y Tomita 1, T Imai 1, T Saito 1, A Katagiri 1, T Tanikawa 1, M Takeda 1, K Takahashi 1
PMCID: PMC2363168  PMID: 10408413

Abstract

Serum-soluble CD95 (sCD95) levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors. Twenty-one of 72 patients had elevated (defined as more than mean of healthy donors + 2 s.d.) sCD95. The disease-specific survival rate was significantly lower in the elevated sCD95 group. Serum sCD95 level was shown to be an independent prognostic factor by univariate and multivariate analysis, indicating a possible significant role in determining treatment strategies. © 1999 Cancer Research Campaign

Keywords: soluble CD95 (Fas/APO-1), renal cell cancer, prognosis

Full Text

The Full Text of this article is available as a PDF (113.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albanese J., Meterissian S., Kontogiannea M., Dubreuil C., Hand A., Sorba S., Dainiak N. Biologically active Fas antigen and its cognate ligand are expressed on plasma membrane-derived extracellular vesicles. Blood. 1998 May 15;91(10):3862–3874. [PubMed] [Google Scholar]
  2. Boise L. H., Minn A. J., Noel P. J., June C. H., Accavitti M. A., Lindsten T., Thompson C. B. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995 Jul;3(1):87–98. doi: 10.1016/1074-7613(95)90161-2. [DOI] [PubMed] [Google Scholar]
  3. Cheng J., Zhou T., Liu C., Shapiro J. P., Brauer M. J., Kiefer M. C., Barr P. J., Mountz J. D. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994 Mar 25;263(5154):1759–1762. doi: 10.1126/science.7510905. [DOI] [PubMed] [Google Scholar]
  4. Fellenberg J., Mau H., Scheuerpflug C., Ewerbeck V., Debatin K. M. Modulation of resistance to anti-APO-1-induced apoptosis in osteosarcoma cells by cytokines. Int J Cancer. 1997 Jul 29;72(3):536–542. doi: 10.1002/(sici)1097-0215(19970729)72:3<536::aid-ijc25>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  5. Hu S., Vincenz C., Ni J., Gentz R., Dixit V. M. I-FLICE, a novel inhibitor of tumor necrosis factor receptor-1- and CD-95-induced apoptosis. J Biol Chem. 1997 Jul 11;272(28):17255–17257. doi: 10.1074/jbc.272.28.17255. [DOI] [PubMed] [Google Scholar]
  6. Jodo S., Kobayashi S., Kayagaki N., Ogura N., Feng Y., Amasaki Y., Fujisaku A., Azuma M., Yagita H., Okumura K. Serum levels of soluble Fas/APO-1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol. 1997 Jan;107(1):89–95. doi: 10.1046/j.1365-2249.1997.d01-901.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Knipping E., Debatin K. M., Stricker K., Heilig B., Eder A., Krammer P. H. Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood. 1995 Mar 15;85(6):1562–1569. [PubMed] [Google Scholar]
  8. Lanigan D. Prognostic factors in renal cell carcinoma. Br J Urol. 1995 May;75(5):565–571. doi: 10.1111/j.1464-410x.1995.tb07408.x. [DOI] [PubMed] [Google Scholar]
  9. Midis G. P., Shen Y., Owen-Schaub L. B. Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy. Cancer Res. 1996 Sep 1;56(17):3870–3874. [PubMed] [Google Scholar]
  10. Nagata S. Fas and Fas ligand: a death factor and its receptor. Adv Immunol. 1994;57:129–144. doi: 10.1016/s0065-2776(08)60672-0. [DOI] [PubMed] [Google Scholar]
  11. Nonomura N., Miki T., Yokoyama M., Imazu T., Takada T., Takeuchi S., Kanno N., Nishimura K., Kojima Y., Okuyama A. Fas/APO-1-mediated apoptosis of human renal cell carcinoma. Biochem Biophys Res Commun. 1996 Dec 24;229(3):945–951. doi: 10.1006/bbrc.1996.1906. [DOI] [PubMed] [Google Scholar]
  12. Owen-Schaub L. B., Angelo L. S., Radinsky R., Ware C. F., Gesner T. G., Bartos D. P. Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis? Cancer Lett. 1995 Jul 20;94(1):1–8. doi: 10.1016/0304-3835(95)03834-j. [DOI] [PubMed] [Google Scholar]
  13. Tomita Y., Bilim V., Kawasaki T., Takahashi K., Okan I., Magnusson K. P., Wiman K. G. Frequent expression of Bcl-2 in renal-cell carcinomas carrying wild-type p53. Int J Cancer. 1996 May 3;66(3):322–325. doi: 10.1002/(SICI)1097-0215(19960503)66:3<322::AID-IJC9>3.0.CO;2-0. [DOI] [PubMed] [Google Scholar]
  14. Tomita Y., Kawasaki T., Bilim V., Takeda M., Takahashi K. Tetrapeptide DEVD-aldehyde or YVAD-chloromethylketone inhibits Fas/Apo-1(CD95)-mediated apoptosis in renal-cell-cancer cells. Int J Cancer. 1996 Sep 27;68(1):132–135. doi: 10.1002/(SICI)1097-0215(19960927)68:1<132::AID-IJC23>3.0.CO;2-C. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES